JP7321194B2 - セレブロン（ｃｒｂｎ）に対するリガンド - Google Patents
セレブロン（ｃｒｂｎ）に対するリガンド Download PDFInfo
- Publication number
- JP7321194B2 JP7321194B2 JP2020571833A JP2020571833A JP7321194B2 JP 7321194 B2 JP7321194 B2 JP 7321194B2 JP 2020571833 A JP2020571833 A JP 2020571833A JP 2020571833 A JP2020571833 A JP 2020571833A JP 7321194 B2 JP7321194 B2 JP 7321194B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- amino
- mixture
- cancer
- tfa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Immunology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023120536A JP7631434B2 (ja) | 2018-06-29 | 2023-07-25 | セレブロン（ｃｒｂｎ）に対するリガンド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692167P | 2018-06-29 | 2018-06-29 | |
| US62/692,167 | 2018-06-29 | ||
| PCT/US2019/039555 WO2020006264A1 (en) | 2018-06-29 | 2019-06-27 | Ligands to cereblon (crbn) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120536A Division JP7631434B2 (ja) | 2018-06-29 | 2023-07-25 | セレブロン（ｃｒｂｎ）に対するリガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530451A JP2021530451A (ja) | 2021-11-11 |
| JP2021530451A5 JP2021530451A5 (enExample) | 2022-06-29 |
| JP7321194B2 true JP7321194B2 (ja) | 2023-08-04 |
Family
ID=68987146
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571833A Active JP7321194B2 (ja) | 2018-06-29 | 2019-06-27 | セレブロン（ｃｒｂｎ）に対するリガンド |
| JP2023120536A Active JP7631434B2 (ja) | 2018-06-29 | 2023-07-25 | セレブロン（ｃｒｂｎ）に対するリガンド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120536A Active JP7631434B2 (ja) | 2018-06-29 | 2023-07-25 | セレブロン（ｃｒｂｎ）に対するリガンド |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11530219B2 (enExample) |
| EP (1) | EP3813829A4 (enExample) |
| JP (2) | JP7321194B2 (enExample) |
| KR (2) | KR20210025061A (enExample) |
| CN (1) | CN112638380B (enExample) |
| AU (1) | AU2019294835B2 (enExample) |
| CA (1) | CA3102214A1 (enExample) |
| WO (1) | WO2020006264A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023139195A (ja) * | 2018-06-29 | 2023-10-03 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | セレブロン（ｃｒｂｎ）に対するリガンド |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190136125A (ko) | 2012-12-21 | 2019-12-09 | 국립연구개발법인 양자과학기술연구개발기구 | 뇌 안에 축적된 타우 단백질을 이미징하기 위한 신규한 화합물 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| JP7293343B2 (ja) | 2018-05-09 | 2023-06-19 | アプリノイア セラピューティクス リミテッド | ヘテロアリール化合物及びその使用 |
| US12582641B2 (en) | 2019-02-25 | 2026-03-24 | Shanghaitech University | Sulfur-containing compound based on glutarimide skeleton and application thereof |
| CN112321566B (zh) | 2019-08-05 | 2022-06-10 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| CA3161455A1 (en) | 2019-11-13 | 2021-05-20 | Aprinoia Therapeutics Limited | Compounds for degrading tau protein aggregates and uses thereof |
| US20230111853A1 (en) * | 2019-12-17 | 2023-04-13 | Orionis Biosciences, Inc. | Compounds modulating protein recruitment and/or degradation |
| ES2980575T3 (es) | 2019-12-18 | 2024-10-02 | Novartis Ag | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos |
| CN113582980B (zh) * | 2020-04-30 | 2023-11-24 | 上海科技大学 | 基于杂环和戊二酰亚胺骨架的化合物及其应用 |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| CR20230614A (es) | 2021-06-03 | 2024-02-01 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2022272061A1 (en) * | 2021-06-25 | 2022-12-29 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| US20250066325A1 (en) * | 2021-11-04 | 2025-02-27 | The Brigham And Women's Hospital, Inc. | Directed degron molecules and applications thereof |
| AU2022419982B2 (en) * | 2021-12-22 | 2026-04-16 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) * | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR102738668B1 (ko) | 2022-02-25 | 2024-12-06 | 계명대학교 산학협력단 | 항암 활성을 갖는 신규 화합물 및 이의 용도 |
| EP4493554A1 (en) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
| WO2024032689A1 (zh) * | 2022-08-10 | 2024-02-15 | 标新生物医药科技(上海)有限公司 | 基于异吲哚啉取代戊二酰亚胺骨架的化合物及其应用 |
| PE20251697A1 (es) | 2022-11-04 | 2025-07-02 | Bristol Myers Squibb Co | Compuestos y su uso para el tratamiento de hemoglobinopatias |
| WO2024167423A1 (en) * | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| WO2024238872A2 (en) * | 2023-05-18 | 2024-11-21 | Firefly Bio, Inc. | Isoindolinone-glutarimide antibody conjugates, and uses thereof |
| WO2025101912A1 (en) * | 2023-11-09 | 2025-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Hells helicase degraders and uses thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004525889A (ja) | 2000-12-27 | 2004-08-26 | セルジーン・コーポレーション | イソインドール−イミド化合物、組成物、およびそれらの使用 |
| JP2007513164A (ja) | 2003-12-02 | 2007-05-24 | セルジーン・コーポレーション | 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物 |
| JP2007532641A (ja) | 2004-04-14 | 2007-11-15 | セルジーン・コーポレーション | 脊髄形成異常症候群の治療及び管理のための免疫調節化合物の使用法、及びそれを含む組成物 |
| JP2009506117A (ja) | 2005-08-31 | 2009-02-12 | セルジーン・コーポレーション | イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法 |
| JP2010512329A (ja) | 2006-12-08 | 2010-04-22 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| JP2012528802A (ja) | 2009-06-01 | 2012-11-15 | ナンジン キャベンディッシュ バイオ−エンジニアリング テクノロジー カンパニー，リミテッド | ３−（置換二水素イソインドールケトン−２−イル）−２，６−ピペリジンジオンの合成方法及びその中間体 |
| JP2017525757A (ja) | 2014-07-11 | 2017-09-07 | セルジーン コーポレイション | 抗増殖性化合物及びその使用方法 |
| JP2017528690A (ja) | 2014-06-27 | 2017-09-28 | セルジーン コーポレイション | セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2358697B1 (en) | 2008-10-29 | 2015-10-21 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer. |
| CN119591582A (zh) * | 2014-04-14 | 2025-03-11 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| CA3101338A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Aminoamide compounds |
| WO2020006264A1 (en) * | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Ligands to cereblon (crbn) |
-
2019
- 2019-06-27 WO PCT/US2019/039555 patent/WO2020006264A1/en not_active Ceased
- 2019-06-27 EP EP19827425.0A patent/EP3813829A4/en active Pending
- 2019-06-27 JP JP2020571833A patent/JP7321194B2/ja active Active
- 2019-06-27 CA CA3102214A patent/CA3102214A1/en active Pending
- 2019-06-27 KR KR1020217001892A patent/KR20210025061A/ko active Pending
- 2019-06-27 CN CN201980057157.9A patent/CN112638380B/zh active Active
- 2019-06-27 AU AU2019294835A patent/AU2019294835B2/en active Active
- 2019-06-27 US US17/255,734 patent/US11530219B2/en active Active
- 2019-06-27 KR KR1020257001993A patent/KR20250020690A/ko active Pending
-
2022
- 2022-11-11 US US17/985,415 patent/US12110292B2/en active Active
-
2023
- 2023-07-25 JP JP2023120536A patent/JP7631434B2/ja active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004525889A (ja) | 2000-12-27 | 2004-08-26 | セルジーン・コーポレーション | イソインドール−イミド化合物、組成物、およびそれらの使用 |
| JP2007513164A (ja) | 2003-12-02 | 2007-05-24 | セルジーン・コーポレーション | 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物 |
| JP2007532641A (ja) | 2004-04-14 | 2007-11-15 | セルジーン・コーポレーション | 脊髄形成異常症候群の治療及び管理のための免疫調節化合物の使用法、及びそれを含む組成物 |
| JP2009506117A (ja) | 2005-08-31 | 2009-02-12 | セルジーン・コーポレーション | イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法 |
| JP2010512329A (ja) | 2006-12-08 | 2010-04-22 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| JP2012528802A (ja) | 2009-06-01 | 2012-11-15 | ナンジン キャベンディッシュ バイオ−エンジニアリング テクノロジー カンパニー，リミテッド | ３−（置換二水素イソインドールケトン−２−イル）−２，６−ピペリジンジオンの合成方法及びその中間体 |
| JP2017528690A (ja) | 2014-06-27 | 2017-09-28 | セルジーン コーポレイション | セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
| JP2017525757A (ja) | 2014-07-11 | 2017-09-07 | セルジーン コーポレイション | 抗増殖性化合物及びその使用方法 |
Non-Patent Citations (1)
| Title |
|---|
| Medicinal Chemistry Communications，2011年，2，1073 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023139195A (ja) * | 2018-06-29 | 2023-10-03 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | セレブロン（ｃｒｂｎ）に対するリガンド |
| JP7631434B2 (ja) | 2018-06-29 | 2025-02-18 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | セレブロン（ｃｒｂｎ）に対するリガンド |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3102214A1 (en) | 2020-01-02 |
| US11530219B2 (en) | 2022-12-20 |
| JP7631434B2 (ja) | 2025-02-18 |
| JP2023139195A (ja) | 2023-10-03 |
| AU2019294835A1 (en) | 2020-12-17 |
| US20230312575A1 (en) | 2023-10-05 |
| EP3813829A4 (en) | 2021-12-08 |
| CN112638380A (zh) | 2021-04-09 |
| JP2021530451A (ja) | 2021-11-11 |
| KR20210025061A (ko) | 2021-03-08 |
| CN112638380B (zh) | 2024-05-24 |
| WO2020006264A1 (en) | 2020-01-02 |
| EP3813829A1 (en) | 2021-05-05 |
| US20210292325A1 (en) | 2021-09-23 |
| US12110292B2 (en) | 2024-10-08 |
| KR20250020690A (ko) | 2025-02-11 |
| AU2019294835B2 (en) | 2025-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7631434B2 (ja) | セレブロン（ｃｒｂｎ）に対するリガンド | |
| JP7328263B2 (ja) | 免疫調節化合物 | |
| US12030892B2 (en) | CRBN modulators | |
| CN113490495A (zh) | Helios的小分子降解剂及其使用方法 | |
| US20240034723A1 (en) | Piperidinyl small molecule degraders of helios and methods of use | |
| WO2020206137A1 (en) | Cdk2/5 degraders and uses thereof | |
| US20240376096A1 (en) | Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof | |
| KR20180110132A (ko) | 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제 | |
| CN113164475A (zh) | Dyrk1a的大环抑制剂 | |
| WO2023056443A1 (en) | Binders of cereblon and methods of use thereof | |
| EP4367115A1 (en) | Degraders of wild-type and mutant forms of lrrk2 and uses thereof | |
| US20230226196A1 (en) | Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220621 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220621 |
|
| TRDD | Decision of grant or rejection written | ||
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230622 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230626 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230725 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7321194 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |